December 15, 2025 a 08:00 am
COR: Fundamental Ratio Analysis - Cencora, Inc.
Cencora, Inc. operates in the healthcare sector, sourcing and distributing pharmaceutical products. With its broad range of services, the company stands as a vital component in the healthcare distribution chain. Its recent rebranding from AmerisourceBergen Corporation to Cencora, Inc. signals a strategic repositioning in its market approach.
Fundamental Rating
The company demonstrates moderate financial strength with focused growth potential, though it faces challenges regarding debt management.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 5 | |
| Return on Assets | 4 | |
| Debt to Equity | 1 | |
| Price to Earnings | 2 | |
| Price to Book | 1 |
Historical Rating
The stable scores over time suggest consistent financial performance of the company.
| Date | Overall Score | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-12-12 | 3 | 4 | 5 | 4 | 1 | 2 | 1 |
| Previous | 3 | 4 | 5 | 4 | 1 | 2 | 1 |
Analyst Price Targets
The stock shows favorable analyst targets, reflecting optimism for potential growth.
| High | Low | Median | Consensus |
|---|---|---|---|
| $415 | $330 | $377 | $373.17 |
Analyst Sentiment
The analyst sentiment suggests a positive outlook with the majority recommending a 'Buy'.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 31 | |
| Hold | 14 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
Cencora, Inc. shows a stable financial position with room for growth, especially for long-term investors. The analyst sentiment reflects a 'Buy' consensus, aligning with positive projected growth targets. However, the low rating in debt to equity suggests potential risks associated with leverage. Overall, it presents a balanced opportunity for investors seeking exposure in the healthcare distribution sector.